Connect with:
Thursday / March 13. 2025

logo
mobile-logo
HomePosts Tagged "Anupam Rasayan"
Agribusiness, Collaborations

Anupam Rasayan expects a 30-35 per cent revenue increase in the financial year ending in March 2026 (FY26), driven by rising demand across pharmaceuticals, polymers, and a recovering agrochemical segment

Demand circumstances have greatly improved, according to Deputy CFO Vishal Thakur, especially in agrochemicals, where volumes are increasing. He stated, “We anticipate growth to continue in Q4 and into FY26 as well. The revenue uptake is largely based on volume.”

Agrochemicals made up 49 per cent of overall sales during the nine months that ended in December 2024, with pharmaceuticals coming in second at 23 per cent, personal care at 17 per cent, and performance materials at 11 per cent. It is anticipated that margins will stay steady between 26-28 per cent.

With revenues increasing 32 per cent year over year (YoY) to Rs 390 crore and profits before interest, tax, depreciation, and amortisation (EBITDA) up 57 per cent YoY to Rs 124 crore, the company had a good third quarter. A positive product mix and consistent demand helped margins grow by 500 basis points (bps) to 31.8 per cent. However, compared to the same period last year, revenue was down 13 for the first nine months of the current fiscal year, while profit was down 24 per cent and the margin was 27.5 per cent. Around 9,000 crore worth of orders have been placed by Anupam Rasayan, and fresh contracts are anticipated to begin contributing in 2025.

Projects signed in 2022 are being commercialized by the corporation, and over the next two years, more recent deals will start to ramp up. According to him, it usually takes 18 to 24 months for a letter of intent to become a commercial product, and an additional two to three years for it to achieve full volume. Additionally, Anupam Rasayan is closely monitoring its working capital cycle, which had experienced some upswing earlier this year. Thakur stated that the medium-term goal is still 180–200 days.

Anupam Rasayan expects a 30-35 per cent

Agribusiness, Agro chems – Chemicals, Company News, Finance, India, Speciality Chemicals

The company has posted total income Rs 413 crore in the January-March quarter of 2023-24 compared to Rs 504.2 crore in the year-ago period.

Chemicals maker Anupam Rasayan India Ltd., one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and year ended March 31, 2024.   Company has reported a 44.26 per cent fall in its consolidated net profit to Rs 40.46 crore for the fourth quarter of 2023-24. Company’s net profit stood at Rs 72.63 crore in FY 2023.

The company has posted total income Rs 413 crore in the January-March quarter of 2023-24 compared to Rs 504.2 crore in the year-ago period, a regulatory filing said.

 Anupam Rasayan posted a 23 per cent drop in consolidated net profit to Rs 167.4 crore for the full fiscal 2023-24 against Rs 216.8 crore in the previous fiscal. For the Year ended March 31, 2024, Anupam Rasayan India posted total revenue at Rs. 1505.3 crore as compared to Rs. 1610.5 crore in FY23; down 7 per cent YoY. Company’s Profit After Tax for FY24 was at 167.4 crore as compared to Rs. 216.8 crore in FY23 – degrowth of 23 per cent YoY.

“The chemical industry, including speciality chemicals, has faced significant headwinds during the last year. However, despite the de-growth in the top line, the company has been able to sustain its profitability and maintain margins at 27 per cent levels on a full-year consolidated basis”, said Anand Desai, Managing Director, Anupam Rasayan .

“We believe that headwinds in the industry may continue for the next two quarters. However, the financial year 2025 will be a year of growth for us with our major focus on polymer and pharmaceutical space,” he added.

The company has posted total income Rs

Agribusiness, Agro chems – Chemicals, Company News, India

These molecules will be produced in Anupam Rasayan’s existing facilities as well as in its soon-to-be-commercialised fluorination plants.

Anupam Rasayan, a leading player in India’s custom synthesis and specialty chemical sector, has recently inked a significant Letter of Intent (LOI) with a prominent Japanese company. The LOI, valued at approximately $90 million (Rs 743 crores) over the next seven years, entails the supply of two advanced intermediates utilising fluorination chemistry. These molecules will be produced in Anupam Rasayan’s existing facilities as well as in its soon-to-be-commercialised fluorination plants.

Commenting on the LOI, Anand Desai, Managing Director of Anupam Rasayan, said, “We are delighted to announce the signing of a Letter of Intent (LOI) with one of the largest Japanese players in Fluorochemicals. Anupam will be the first company in India to manufacture these key molecules domestically, with applications spanning both pharmaceuticals and engineering fluids. The signing of this LOI also signifies the addition of a prestigious new customer to our portfolio.”

Desai further highlighted the role of the Business Development Team in securing the deal, emphasizing their exceptional proficiency in creating opportunities that align with the company’s global expansion objectives.

He added, “This landmark LOI not only expands and diversifies our customer base but also solidifies our position in the Japanese markets as one of the most reliable partners for supplying specialized molecules to global majors.”

These molecules will be produced in Anupam

Agro chems – Chemicals, Company News, India

The company will supply two novel life science related specialty chemicals for the next three years

Anupam Rasayan has signed two contracts with one of the leading European crop protection companies for supplying two new life science related specialty chemicals.

The company will supply these products for the next three years under the contract. These products will be manufactured in the company’s existing manufacturing facilities. The provision of two novel life science related specialty chemicals. The deal calls on the firm to deliver these items for the next three years. These goods will be manufactured at their current facilities.

These goods were conceptualised in three months, and it took less than 18 months for them to be commercialised. We were able to supply these items in such a short amount of time due to our customer’s urgent request. This displays the company’s commitment to the customer as well as our outstanding R&D skills, said company in release.

These contracts are consistent with the company’s aim of expanding wallet share and strengthening relationships with current clients. Having these additions, the total number of molecules with this MNC now stands at 6.

Anupam Rasayan is working with a few more MNC clients, and anticipates that 20 to 25 specialty goods will be added to its product range in the near future as part of Europe plus one plan.

The company will supply two novel life

Company News, Finance

The company posted a 116 per cent growth in its consolidated net profit at Rs 152 crore for fiscal 2021-22

Surat-based Anupam Rasayan India will raise funds for an aggregate amount not exceeding Rs 800 crore through the issue of equity shares by way of a qualified institution’s placement (QIP), under the relevant provisions of applicable laws and subject to the approval of the company’s shareholders and receipt of applicable regulatory approvals.

The company has posted a 116 per cent growth in its consolidated net profit at Rs 152 crore for fiscal 2021-22. The company’s revenues grew 31 per cent during the fiscal year at Rs 1,066 crore against Rs 810 crore in FY 2021. Net profit in the fourth quarter more than doubled and reached Rs 46.102 crores as against Rs 22.144 crores last year.

The company posted a 116 per cent